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RESUMO – A doença de Behçet é uma vasculite sistémica crónica e recidivante que pode levar a um aumento significativo da morbi-
lidade e mortalidade. Após superar o desafio em fazer o seu diagnóstico atempado, que muitas vezes se impõe, surge a dificuldade 
no seu tratamento.
Relata-se um caso de um doente que se apresentou com uma erupção acneiforme reveladora de doença de Behçet, refratária à 
terapia convencional, que respondeu mais tarde e completamente, ao adalimumab.
Na literatura científica, embora faltem ensaios clínicos controlados e randomizados, há já evidência significativa que suporta o papel 
dos agentes anti-TNF como um importante avanço terapêutico na doença de Behçet, particularmente em casos graves, refratários 
ou intolerantes à imunossupressão clássica.  
PALAVRAS-CHAVE – Adalimumab; Erupções Acneiformes; Factor de Necrose Tumoral alfa /antagonistas & inibidores; Síndro-
me de Behçet.
Recalcitrant Acneiform Eruption Revealing Behçet’s 
Disease: A Case with Late but Successful Response to 
Adalimumab 
ABSTRACT – Behçet's disease is a systemic vasculitis with a chronic-relapsing course, which can lead to significant morbidity and 
mortality. From the often-compelling challenge of making a prompt diagnosis comes the difficulty in its treatment.
We report the case of a patient with an acneiform skin eruption revealing Behçet's disease that was refractory to conventional therapy 
and later completely responded to adalimumab. 
Although randomized controlled clinical trials are lacking in the literature, there is already significant evidence supporting anti-TNF 
agents as a major therapeutic advance in Behçet's disease, particularly in cases that are severe, refractory or intolerant to classical 
immunosuppression.
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BACKGROUND
Behçet's disease (BD) has a wide clinical spectrum along 
different degrees of severity. The main clinical manifestations 
include recurrent oral and genital ulcers, skin lesions and 
uveitis, but practically all organs can be affected. There are 
no clinical or laboratory findings pathognomonic of BD, the-
refore the diagnosis is based on clinical criteria after exclu-
sion of other conditions.1,2
BD is associated with significant morbidity and morta-
lity, especially when there is neurological, cardiovascular, 
gastrointestinal or ophthalmic involvement, the latter po-
tentially leading to vision loss.3 Poorer prognosis is related 
to male gender, young age at diagnosis, positive HLA-B51, 
arterial involvement and frequent outbreaks.3-5 The thera-
peutic approach depends on the clinical presentation and 
its severity. Insufficient or total lack of disease activity control 
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with conventional immunosuppressive therapy represents a 
need for new drugs. With the discovery of TNF-α as a cen-
tral inflammatory mediator in BD, anti-TNF agents, mainly 
infliximab and adalimumab, have been used with promising 
results concerning efficacy and safety.6-8
CASE REPORT
A 31-year-old Caucasian man, with no relevant medical 
history, was referred to the Dermatology department with pa-
pulo-pustular lesions and atrophic scars on the trunk and limbs 
that were present for one year, unresponsive to minocycline 
and partially responsive to oral prednisone 0.5 mg/kg/day 
(Fig.1). Blood test results were unremarkable, with negative au-
toimmune and viral serologies. Skin histopathology from one 
of these lesions in the back performed eight months previously 
suggested pityriasis lichenoides et varioliformis acuta (PLEVA) 
but there was no clinical evidence of this diagnosis. Skin biopsy 
was repeated and histopathologic evaluation disclosed a deep 
folliculitis rich in neutrophils with vascular involvement, with no 
observable microorganisms (Fig. 2). 
The patient showed partial improvement with oral pred-
nisolone 0.5 mg/kg/day and lack of response to dapsone 50 
mg/day, introduced during the corticoid tapering once the 
biopsy was compatible with a neutrophilic dermatosis. It was 
suspended four months later due to the lack of response and 
the onset of anemia when the dose was increased to 100 mg/
day, one month after the beginning of dapsone. Prednisolone 
was always maintained and adjusted according to the clini-
cal state. Two months after stopping dapsone, the number of 
skin lesions increased and worsened, some of them exhibiting 
central necrosis. During this time, the patient struggled with a 
very slowly healing of a post-traumatic wound on the nasal 
bridge, which led us to perform a pathergy test, with a posi-
tive result. When questioned, the patient confirmed previously 
Revista SPDV 75(4) 2017; Cutaneous Behçet treated with adalimumab; Júlia Vide, Sofia Lopes, Sofia Magina, Filomena Azevedo.
Figure 1 - Papulo-pustular lesions and atrophic scars on the trunk and limbs.
Figure 2 - Histology: deep folliculitis rich in neutrophils with accompanying vasculitis. A) Hematoxylin-eosin original magnification × 40; B) Hematoxy-
lin-eosin original magnification x 200; C) Hematoxylin-eosin original magnification × 400.
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devalued episodes of oral and genital ulcers for more than five 
years, which resolved in a few days, with no scars, and occur-
red nearly five times per year, hence gathering criteria for the 
diagnosis Behçet Disease, according to the International Crite-
ria for Behçet Disease (ICBD).2 During the subsequent six mon-
ths’ follow-up, four additional episodes of oral aphthosis were 
identified and a left knee oligoarthritis was detected. Arthritis 
and widespread deep folliculitides of the skin were the most li-
miting signs. No response was seen with colchicine 2 mg/day. 
Prednisolone 0.5 mg/kg/day provided only partial improve-
ment. A trial of azathioprine 50 mg/day had to be quickly sus-
pended after severe hepatotoxicity. Subcutaneous adalimumab 
40mg biweekly was then introduced, with a slow and gradual 
improvement, allowing corticosteroid suspension four months 
later. Complete remission was achieved six months after star-
ting adalimumab and remission remains after 24 months of 
follow-up on continuous therapy (Fig. 3).
DISCUSSION
There are still some difficulties in establishing an exact diag-
nosis of BD, because of its widely variable clinical presentations 
and limited diagnostic tests. Prompt recognition of the diverse 
dermatological aspects that, although unspecific per se, may 
suggest BD when in association, can be an important clue to 
an early diagnosis. In addition to oral and genital aphthosis, 
erythema nodosum, papulo-pustular lesions and the presence 
of pathergy are considered major diagnostic criteria of BD.1,2
Papulo-pustular lesions, folliculitis, pseudofolliculitis and 
acneiform eruption are all terms that have been applied for the 
same type of lesion, which is polymorphous in nature, and one 
of the most common findings in BD, reported in 28% – 96% 
of cases.9 However, since these lesions may be confused with 
acne vulgaris, some authorities do not recommend using pa-
pulo-pustular lesions for diagnostic criteria.10 Still, these lesions 
may hold additional features that might be helpful to enhance 
their specificity: post-puberty onset under no steroid treatment, 
systemic symptoms, widespread distribution affecting face, 
limbs, trunk and buttocks, cutaneous ulcers healing with scar 
formation and neutrophilic non-follicular or vasculitic lesions 
on histopathology.9-11
Current evidence suggests that early treatment may, 
to some extent, control and perhaps change the course of 
BD.2,3,7 The new ICBD, derived from multinational data, exhi-
bit much improved sensitivity over the previously used In-
ternational Study Group of Behçet Disease criteria (ISGBD) 
(93.9% vs 81.2%), while maintaining reasonable specificity 
(92.1% vs 95.9%). It allows the early recognition and referral 
to expert centres, thus leading to prompt diagnosis and treat-
ment, with salutary results. According to the ICBD, a patient 
scoring 4 or more points is classified as having BD. Ocular le-
sions, oral aphthosis and genital ulcers are assigned 2 points 
each, while skin lesions, central nervous system involvement, 
vascular manifestations and a positive pathergy test are as-
signed 1 point each.2
The aim of the therapeutic strategy in BD is to induce and 
maintain remission in order to minimize potential irreversi-
ble damage and improve patients’ quality of life. Treatment 
selection is based on the organ involved and on the assess-
ment of its severity. Based largely on case reports and isolated 
observations, systemic therapy including corticosteroids, col-
chicine, dapsone, azathioprine, methotrexate, cyclosporine, 
cyclophosphamide, mycophenolate mofetil and thalidomide 
has been used. Nevertheless, a few patients have relapses, 
exhibit life-threatening events, develop disease-related com-
plications or present side-effects to standard immunosuppres-
sive agents. In these conditions, TNF-α antagonism emerges 
as a valid option.6-8
Anti-TNF therapy has been shown to be effective, with sus-
tained efficacy and safety in more than 85% of severe or re-
fractory BD manifestations, significantly increasing remissions 
and decreasing corticosteroid prescription.7,8 Reportedly, when 
introduced later in the disease course, response to anti-TNF 
drugs is weaker, especially in the setting of ophthalmic dama-
ge, which may be irreversible.12,13
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Figure 3 - Complete and sustained remission with adalimumab treatment.
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Even though most of the experience with anti-TNF inhi-
bition in BD derives from infliximab, adalimumab seems to 
have similar efficacy and safety profile.7,8 In addition, a recent 
paper has showed successful treatment of 17 BD patients with 
predominant mucocutaneous lesions, when switched from 
infliximab to adalimumab.14 Late response to anti-TNF, as in 
the above mentioned case has been described, although not 
usual.15 Recent studies emphasize that Th17 cells also have 
a significant role in BD, presenting as an additional possible 
therapeutic target.10
Our patient presented with an acneiform eruption, while 
undervaluing the preceding manifestations of his BD (i.e. epi-
sodes of oral and genital ulcerations) and these were there-
fore undisclosed spontaneously. A few acne vulgaris-directed 
therapies were initially tried but failed, raising clinical suspi-
cion of BD. Clinician’s should therefore be aware of isolated 
acneiform eruptions as a presenting form of BD and include 
BD in the differential of acne-vulgaris, while referring to parti-
cular features that suggest the former diagnosis. Regarding BD 
treatment, although randomized controlled clinical trials are 
lacking, there is already significant evidence supporting anti-
-TNF inhibition as a major therapeutic advance, particularly in 
severe or refractory disease, in patients who are intolerant to 
classical immunosuppression and in patients with BD manifes-
tations that significantly reduce their quality of life.
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